UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antihypertensive therapy and the risk of new-onset diabetes

Diabetes care, 2006-05, Vol.29 (5), p.1167-1169

2006

Volltextzugriff (PDF)

The metabolic syndrome: a glance at its history

Journal of hypertension, 2006-04, Vol.24 (4), p.621-626

2006

Volltextzugriff (PDF)

Actions of Peroxisome Proliferator–Activated Receptors–γ Agonists Explaining a Possible Blood Pressure–Lowering Effect

American Journal of Hypertension, 2006-06, Vol.19 (6), p.646-653

2006

Volltextzugriff (PDF)

Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?

American Journal of Hypertension, 2003-08, Vol.16 (8), p.689-697

2003

Volltextzugriff (PDF)

Level of kidney function determines cardiovascular fate after coronary bypass graft surgery

Circulation (New York, N.Y.), 2006-02, Vol.113 (8), p.1046-1047

2006

Volltextzugriff (PDF)

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

Journal of hypertension, 2004-09, Vol.22 (9), p.1769-1777

2004

Volltextzugriff (PDF)

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

American journal of hypertension, 2005-02, Vol.18 (2), p.227-234

2005

Volltextzugriff (PDF)

Do the Metabolic Effects of β Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?

The journal of clinical hypertension (Greenwich, Conn.), 2006-05, Vol.8 (5), p.351-356

2006

Volltextzugriff (PDF)

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension : An open-label observational study

Metabolism, clinical and experimental, 2005-09, Vol.54 (9), p.1236-1242

2005

Volltextzugriff (PDF)

Are β Blockers Passé for the Treatment of Hypertension?

The journal of clinical hypertension (Greenwich, Conn.), 2006-04, Vol.8 (4), p.239-240

2006

Volltextzugriff (PDF)

Cardiometabolic syndrome and chronic kidney disease: what is the link?

Journal of the cardiometabolic syndrome, 2006, Vol.1 (1), p.58-65

2006

Volltextzugriff (PDF)

An Economic Evaluation of the 2003 European Society of Hypertension–European Society of Cardiology Guidelines for the Management of Mild-to-Moderate Hypertension in Greece

American journal of hypertension, 2005-09, Vol.18 (9), p.1233-1240

2005

Volltextzugriff (PDF)

P-649: Rosiglitazone lowers C-reactive protein levels in hypertensive type 2 diabetic patients

American journal of hypertension, 2005-05, Vol.18 (S4), p.244A-244A

2005

Volltextzugriff (PDF)

P-606: Efficacy and costs of treatment of mild-to-moderate uncomplicated hypertension in Greece

American journal of hypertension, 2005-05, Vol.18 (S4), p.228A-228A

2005

Volltextzugriff (PDF)

P-607: Pharmacoeconomic analysis of antihypertensive agents in Greece

American journal of hypertension, 2005-05, Vol.18 (S4), p.228A-228A

2005

Volltextzugriff (PDF)

P-472: Coexistence of hypertension and hypercholesterolemia in employees of factories of northern greece

American journal of hypertension, 2004-05, Vol.17 (S1), p.205A-205A

2004

Volltextzugriff (PDF)

P-508: The effects of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients

American journal of hypertension, 2004-05, Vol.17 (S1), p.218A-219A

2004

Volltextzugriff (PDF)

Actions of Peroxisome Proliferator-Activated Receptors-[gamma] Agonists Explaining a Possible Blood Pressure-Lowering Effect

American journal of hypertension, 2006-06, Vol.19 (6), p.646

2006

Volltextzugriff (PDF)

Rosiglitazone Improves Insulin Sensitivity and Glycemic Control in Patients with Both Poorly Controlled Type 2 Diabetes and Hypertension

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A522

2005

Volltextzugriff (PDF)

The Effect of Rosiglitazone on Safety Parameters of Patients with Type 2 Diabetes and Hypertension

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A522

2005

Volltextzugriff (PDF)

Efficacy and costs of treatment of mild-to-moderate uncomplicated hypertension in Greece

American journal of hypertension, 2005-05, Vol.18 (5), p.A228-A228

2005

Volltextzugriff (PDF)

PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?

Current hypertension reviews, 2006-02, Vol.2 (1), p.47-60

2006

Volltextzugriff (PDF)

Pharmacoeconomic analysis of antihypertensive agents in Greece

American journal of hypertension, 2005-05, Vol.18 (5), p.A228-A228

2005

Volltextzugriff (PDF)

Coexistence of hypertension and hypercholesterolemia in employees of factories of northern greece

American journal of hypertension, 2004-05, Vol.17 (5), p.S205-S205

2004

Volltextzugriff (PDF)

The effects of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients

American journal of hypertension, 2004-05, Vol.17 (5), p.S218-S219

2004

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)
Buchkapitel
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Antihypertensive therapy and the risk of new-onset diabetes

The metabolic syndrome: a glance at its history

Actions of Peroxisome Proliferator–Activated Receptors–γ Agonists Explaining a Possible Blood Pressure–Lowering Effect

Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials?

Level of kidney function determines cardiovascular fate after coronary bypass graft surgery

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

Do the Metabolic Effects of β Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension : An open-label observational study

Are β Blockers Passé for the Treatment of Hypertension?

Cardiometabolic syndrome and chronic kidney disease: what is the link?

An Economic Evaluation of the 2003 European Society of Hypertension–European Society of Cardiology Guidelines for the Management of Mild-to-Moderate Hypertension in Greece

P-649: Rosiglitazone lowers C-reactive protein levels in hypertensive type 2 diabetic patients

P-606: Efficacy and costs of treatment of mild-to-moderate uncomplicated hypertension in Greece

P-607: Pharmacoeconomic analysis of antihypertensive agents in Greece

P-472: Coexistence of hypertension and hypercholesterolemia in employees of factories of northern greece

P-508: The effects of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients

Actions of Peroxisome Proliferator-Activated Receptors-[gamma] Agonists Explaining a Possible Blood Pressure-Lowering Effect

Rosiglitazone Improves Insulin Sensitivity and Glycemic Control in Patients with Both Poorly Controlled Type 2 Diabetes and Hypertension

The Effect of Rosiglitazone on Safety Parameters of Patients with Type 2 Diabetes and Hypertension

Efficacy and costs of treatment of mild-to-moderate uncomplicated hypertension in Greece

PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?

Pharmacoeconomic analysis of antihypertensive agents in Greece

Coexistence of hypertension and hypercholesterolemia in employees of factories of northern greece

The effects of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients

Suchergebnisse filtern